Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, Inc. (NASDAQ:MLYS), reported sales of the company’s common stock totaling $556,671 across two transactions on July 13 and July 15, 2026. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, which was adopted on October 6, 2025. The sales came as the stock traded at $27.33, with shares declining 5.7% over the past week, according to InvestingPro data. The platform’s Fair Value analysis suggests the stock is currently overvalued.
On July 13, Mr. Malcom sold 14,058 shares of Mineralys Therapeutics common stock at a weighted-average price of $27.5798 per share. The individual prices for these sales ranged from $26.965 to $27.750. Two days later, on July 15, an additional 6,349 shares were sold at a weighted-average price of $26.6112 per share, with transaction prices ranging from $26.41 to $27.15.
Concurrently with the initial sales on July 13, Mr. Malcom also acquired common stock through the exercise of stock options, totaling $102,365. This included 3,542 shares acquired at an exercise price of $10.20 per share, 4,167 shares at $14.25 per share, and 6,349 shares at $1.08 per share. The options exercised had varying vesting schedules; some vested in monthly installments over a four-year period, while others vested 25% on the first anniversary of the grant date, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Following these reported transactions, Rodman David Malcom directly holds 51,384 shares of Mineralys Therapeutics common stock. For deeper insights into MLYS’s financial health and insider activity patterns, InvestingPro offers 7 additional ProTips and a comprehensive Pro Research Report covering this $2.4 billion biotech company.
In other recent news, Mineralys Therapeutics Inc. announced a public offering of 5,660,378 shares of common stock priced at $26.50 per share, aiming to raise approximately $150 million in gross proceeds. The company also secured $750 million through a combination of debt, equity, and a royalty deal to strengthen its financial position. This includes a payment to Tanabe Pharma Corporation to eliminate future royalty obligations related to lorundrostat, with Tanabe assigning its intellectual property rights to Mineralys.
Analyst firm Jefferies reiterated a Hold rating on Mineralys stock, citing potential acquisition interest as the company’s new drug application undergoes FDA review. Meanwhile, H.C. Wainwright maintained a Buy rating, highlighting data presented by Mineralys at a European conference, which focused on lorundrostat’s efficacy in treating hypertension. Additionally, Mineralys shared clinical data from the Phase 3 Launch-HTN trial, revealing that lorundrostat was evaluated in patients with uncontrolled or resistant hypertension, including those with chronic kidney disease. These developments reflect Mineralys’ ongoing efforts to advance its drug portfolio and financial strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News